Kura Oncology, Inc.
HealthcareNASDAQ:KURA · NASDAQ Global Select
+$0.19 today
Vol 1.29M · Avg 2.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-160.0%
avg -45.5%
ROIC
-48.8%
avg -33.7%
ROA
-37.7%
avg -29.5%
Analysis
ROA is currently the strongest return metric at -37.7% versus its period average of -29.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Troy Edward Wilson | Chairman, Chief Executive Officer & President | $1.44M | — | 57 | $435,456.00 | 0.49% |
Kathleen Ford | Chief Operating Officer | $926,501.00 | — | 79 | $153,560.00 | 0.17% |
Mollie Leoni | Chief Medical Officer | $855,297.00 | — | 48 | $269,566.00 | 0.30% |
Brian T. Powl | Chief Commercial Officer | $814,998.00 | — | 52 | $173,614.00 | 0.20% |
Teresa Brophy Bair | Chief Legal Officer & Corporate Secretary | $745,021.00 | — | 55 | $226,931.00 | 0.26% |
Roger Bakale | Senior Vice President of Manufacturing & Supply Chain | — | — | — | — | — |
Francis J. Burrows | Chief Scientific Officer | — | — | 64 | $32,424.00 | 0.04% |
Thomas Doyle | Senior Vice President of Finance & Accounting | — | — | 55 | $35,000.00 | 0.04% |
Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | — | — | — | — | — |
Samir Vattompadam | Senior Vice President of Global Program Leadership | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$713,346.45
Sells
33
$2.00M
Net Sentiment
$1.28M
Net selling
Most Active
DOYLE THOMAS JAMES
7 transactions
1–10 of 36
Analysis
Insiders reported 3 buys worth $713,346.45 and 33 sells worth $2.00M over the last 12 months. That adds up to net selling of $1.28M. DOYLE THOMAS JAMES was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages KURA?
Kura Oncology, Inc. (KURA) lists 10 active executives. The top listed executive is Kathleen Ford, Chief Operating Officer.
Are KURA insiders buying or selling?
Recent insider activity shows net buying of $70.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.